MyVisionTest News Archive

Displaying news items tagged with Lucentis (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Lucentis
Mar 28, 2011
While visual improvement is frequently achieved following the almost universally accepted monthly injection for 3 months initiation phase of Lucentis (ranibizumab), the only proven treatment regime to maintain the initial gain in visual acuity (VA) is the monthly injection of Lucentis. The advantages of this regimen include simplicity and the...

Full Article


Age-related macular degeneration
Mar 28, 2011
In patients with neovascular age-related macular degeneration (AMD) retinal function, as measured using multifocal electroretinography (mfERG), improved following treatment with intravitreal Lucentis (ranibizumab). The electroretinogram (ERG) is a recording of the electrical activity of the retinal cells located at the back of the eye when...

Full Article


National Health Service
Mar 27, 2011
In draft guidance issued this month, the National Institute for Health and Clinical Excellence (NICE) in Britian has not recommended Lucentis (ranibizumab) for treating diabetic macular oedema (DMO). This draft guidance has been issued for consultation. NICE has not yet issued final guidance to the NHS. People with diabetes frequently...

Full Article


Diabetes
Mar 27, 2011
The National electronic Library for Medicines in the European Union (EU) has published a review that summarizes the clinical trial data investigating the safety and effectiveness of Lucentis, Macugen, and Iluvien in the treatment of diabetic macular edema. Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy and can...

Full Article


Mar 19, 2011
A very interesting time-lapse video using a series fundus photographs during treatment of wet AMD with Lucentis showing exacerbations and remissions over a 2 year...

Full Article


Diabetes
Mar 8, 2011
Genentech announced today that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with diabetic macular edema (DME), met its primary endpoint. DME is a serious complication of diabetes that affects up to 10 percent of people with the disease and can lead to blurred vision, severe vision loss and blindness....

Full Article


Central serous chorioretinopathy
Mar 7, 2011
The authors report on a patient with CSCR that developed subretinal fibrosis that responded favorably to treatment with intravitral Lucentis (ranibizumab). Central serous chorioretinopathy (CSCR) manifests as detachment of the macula and can be attributed to focal or multifocal leakage in the retinal pigment epithelium (RPE). Increased...

Full Article


Children
Feb 27, 2011
Anti-VEGF drugs were safe and effective in the treatment of choroidal neovascular membranes (CNVMs) secondary to a variety of etiologies in 4 children, according to a new study. In the pediatric population, the diagnosis and management of choroidal neovascular membranes (CNVM) is challenging. Pediatric CNVMs are an infrequent but significant...

Full Article


CCTV low vision aid
Feb 27, 2011
A new study finds that Lucentis (ranibizumab) significantly improves the vision of patients with very poor baseline visual acuity secondary to neovascular age-related macular degeneration (AMD). Treatment with anti-VEGF drugs has become the standard treatment of choroidal neovascularisation (CNV) because of AMD. However, information is limited...

Full Article


Uveitis
Feb 27, 2011
Intravitreal injections with anti-VEGF agents such as Avastin (bevacizumab) and Lucentis (ranibizumab) have been increasingly used for the treatment of retinal disorders over the past years. Although both drugs are often repeatedly injected in patients with choroidal neovascularizations, serious adverse events are rare. Here, is presented a case...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More